Array BioPharma, Inc.
3200 Walnut Street
Boulder,
CO 80301
Phone: 303-381-6600
Fax: 303-386-1390
Web Site: http://www.arraybiopharma.com
| REUTERS ABRIDGED BUSINESS SUMMARY | |
| Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer, inflammatory, and metabolic diseases in North America, Europe, and Asia Pacific. Its programs under development pipeline include ARRY-403, a glucokinase activator for Type 2 diabetes, that is in a Phase 1 multiple ascending dose trial; ARRY-162, a MEK inhibitor for cancer that is in a Phase 1 trial; ARRY-380, an ErbB-2 inhibitor for breast cancer, which is in Phase 1 dose escalation trial; and ARRY-520, a KSP inhibitor that is in Phase 1 expansion trial in solid tumors and Phase 1/2 acute myeloid leukemia and multiple myeloma trials. The companys programs also comprise ARRY-614, a p38/Tie 2 dual inhibitor, which is in Phase 1 trial in myelodysplastic syndrome patients; ARRY-543, an ErbB family (ErbB-2/EGFR) inhibitor for solid tumors that is in Phase 1b combination trials; ARRY-797, a p38 inhibitor for subacute pain and cancer supportive care indications; and ARRY-300, an MEK that completed Phase 1 trial in healthy volunteers. It has collaborations with Celgene Corporation focusing on the discovery, development, and commercialization of novel therapeutics in cancer and inflammation; Genentech, Inc. to develop cancer programs; and AstraZeneca, PLC, which licensed the companys three MEK inhibitors for cancer, including AZD6244 (ARRY-886). The company was founded in 1998 and is headquartered in Boulder, Colorado. |
|
| Key Statistics | More from Reuters
Expanded Business Description |
| |
| REUTERS ABRIDGED FINANCIAL SUMMARY | |
| | Pay | Exercised | Mr. Robert E. Conway , 56
Chief Exec. Officer |
$
513.00K |
$
0 | Dr. Kevin Koch Ph.D., 50
Co-Founder, Pres, Chief Scientific Officer |
$
405.00K |
$
0 | Mr. David L. Snitman Ph.D, 58
Co-Founder, Chief Operating Officer, VP of Bus. Devel. |
$
326.00K |
$
119.00K | Mr. R. Michael Carruthers , 52
Chief Financial Officer and Principal Accounting Officer |
$
271.00K |
$
0 | Mr. John R. Moore , 46
VP, Sec. and Gen. Counsel |
$
291.00K |
$
0 |
|
|
|
Dollar amounts are as of
31-Dec-09
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
Help
Profile
Reuters offers more in-depth
